PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion Reveals Frost & Sullivan - New analysis from Frost & Sullivan, Global Diabetes Market, finds that the market earned revenues of $27.00 billion in 2008 and estimates this to reach $44.70 billion in 2015
Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion Reveals Frost & Sullivan

 

NewswireToday - /newswire/ - London, United Kingdom, 2009/08/19 - New analysis from Frost & Sullivan, Global Diabetes Market, finds that the market earned revenues of $27.00 billion in 2008 and estimates this to reach $44.70 billion in 2015.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Increasing knowledge related to the pathology of diabetes will support the introduction of improved drugs to treat the disease. As healthcare moves towards the ideal of preventive medicine, there are a few companies conducting research on diabetes vaccines. If they succeed, the entire market landscape is bound to undergo instant change.

New analysis from Frost & Sullivan (pharma.frost.com), Global Diabetes Market, finds that the market earned revenues of $27.00 billion in 2008 and estimates this to reach $44.70 billion in 2015.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an email to Katja Feick, Corporate Communications, at katja.feick[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, a brief brochure will be sent to you by email.

"Improved therapies and innovative drug delivery techniques are anticipated to revolutionise the global diabetes market by 2015," notes Frost & Sullivan Programme Leader Sylvia Miriyam Findlay. "As healthcare moves towards preventive medicine, the search for a cure for diabetes looks promising."

The emergence of newer classes of drugs to treat diabetes and their co-morbidities is changing the diabetes market landscape. Long-acting GLP-1 analogs are likely to gain significance and almost match the importance of insulin in the near future. This trend is likely to be beneficial for Type-2 diabetics who have not responded to other oral anti-diabetic agents.

The Food and Drug Administration (FDA) has detailed stringent policies for the approval of diabetic drugs. These policies compel lengthier clinical trials, often resulting in the delayed launch of new drugs and increased drug development costs.

"The not-so conducive regulatory environment, varying price controls across countries and parallel trading hinders the growth of the global diabetes market," adds Findlay. "In addition, generic competition arising due to patent expiries of major drugs is also restraining market expansion."

Despite these obstacles, the diabetes market is, and will continue to be, a lucrative segment of the healthcare industry. Numerous innovative drugs and drug delivery devices are currently being researched. Given these are successful; the launch of such drugs and devices will further open up the market and boost revenue generation.

"Asian markets, especially India and China, offer tremendous prospects for growth," concludes Findlay. "These markets have large diabetic populations and, with the number of undiagnosed diabetics increasing, lucrative untapped opportunities are emerging for pharmaceutical companies."

Global Diabetes Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: European HIV/AIDS Therapeutics Market, Strategic Analysis of the European Specialty Pharma Market and, Emerging Generic Pharmaceuticals Market in Europe. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents.

Global Diabetes Market / M3C7

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion Reveals Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Katja Feick 
+49 (0) 69 7703343 katja.feick[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)